	US 11,732,040 B2
	Anti-CD33 and anti-CD7 combination treatment
Tiffany Jane Daniels, Cheshire (GB)
Assigned to BIVICTRIX LIMITED, Macclesfield (GB)
Appl. No. 16/767,470
Filed by BiVictriX Limited, Macclesfield (GB)
PCT Filed Nov. 27, 2018, PCT No. PCT/GB2018/053429 § 371(c)(1), (2) Date May 27, 2020, PCT Pub. No. WO2019/102234, PCT Pub. Date May 31, 2019.
Claims priority of application No. 1719646 (GB), filed on Nov. 27, 2017.
Prior Publication US 2021/0139580 A1, May 13, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 35/17 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/732 (2013.01); C07K 2317/77 (2013.01); C07K 2319/55 (2013.01)]

9 Claims

1. A method of treating a CD7+CD33+ hematological malignancy by administering a cell inhibiting agent that bispecifically binds to CD33 and CD7, wherein said cell inhibiting agent comprises a cytotoxin linked to a bispecific antibody or antigen binding portion thereof, including a CD7 binding portion and a CD33 binding portion.